Astrazeneca (AZN) Cash from Financing Activities (2009 - 2026)

Astrazeneca has reported Cash from Financing Activities for 18 years, with the latest figure at -$47.0 million in Q2 2026.

• On a quarterly basis, Cash from Financing Activities fell 103.68% year-over-year to -$47.0 million in Q2 2026; TTM through Jun 2026 was $5.5 billion, a 24.33% decrease from a year earlier, with the FY2025 full-year figure at $7.8 billion, up 100.13% from the prior year.
• Cash from Financing Activities was -$47.0 million for Q2 2026 at Astrazeneca, down from $1.6 billion in the prior quarter.
• The five-year high for Cash from Financing Activities was $5.0 billion in Q4 2023, with the low at -$47.0 million in Q2 2026.
• Average Cash from Financing Activities over 5 years is $1.8 billion, with a median of $1.6 billion recorded in 2024.
• The sharpest annual moves came in 2025 and 2026: Cash from Financing Activities jumped 3269.86% in 2025, then tumbled 103.68% in 2026.
• Over 5 years, Cash from Financing Activities stood at $4.7 billion in 2022, then advanced by 5.94% to $5.0 billion in 2023, then sank by 65.33% to $1.7 billion in 2024, then slumped by 48.09% to $896.0 million in 2025, then sank by 105.25% to -$47.0 million in 2026.
• The last three Cash from Financing Activities figures came in at -$47.0 million (Q2 2026), $1.6 billion (Q1 2026), and $896.0 million (Q4 2025), per Business Quant data.